Korro Bio Q3 EPS $(1.92) Beats $(2.59) Estimate, Sales $1.090M Beat $578.222K Estimate

Korro Bio (NASDAQ: KRRO) reported quarterly losses of $(1.92) per share which beat the analyst consensus estimate of $(2.59) by 25.98 percent. This is a 15.04 percent increase over losses of $(2.26) per share from the same period last year. The company reported quarterly sales of $1.090 million which beat the analyst consensus estimate of $578.222 thousand by 88.51 percent.